1201438-56-3 | Duvelisib

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$26.00	$18.00
5mg	95%	in stock	$62.00	$44.00
10mg	95%	in stock	$121.00	$85.00
25mg	95%	in stock	$175.00	$123.00
50mg	95%	in stock	$227.00	$159.00
100mg	95%	in stock	$371.00	$260.00
1g	95%	in stock	$2,176.00	$1,523.00

Description

• Catalog Number: AA34002
• Chemical Name: Duvelisib
• CAS Number: 1201438-56-3
• Molecular Formula: C22H17ClN6O
• Molecular Weight: 416.863
• MDL Number: MFCD15144635
• SMILES: Clc1cccc2c1c(=O)n(c(c2)[C@@H](Nc1ncnc2c1nc[nH]2)C)c1ccccc1

Computed Properties

• Complexity: 668
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 4.1

Upstream Synthesis Route

Duvelisib is a potent and selective inhibitor of phosphoinositide 3-kinases (PI3Ks), specifically targeting the delta and gamma isoforms. In chemical synthesis, Duvelisib plays a crucial role as a key reagent for modulating intracellular signaling pathways that are involved in various cellular processes. By inhibiting PI3K delta and gamma isoforms, Duvelisib can effectively block the PI3K/AKT/mTOR pathway, which is critical for cell growth, differentiation, and survival.Furthermore, Duvelisib can be utilized in chemical synthesis to study the impact of PI3K inhibition on cellular functions and to investigate its potential therapeutic applications in various diseases, including cancer and autoimmune disorders. Its ability to selectively target specific PI3K isoforms makes Duvelisib a valuable tool for designing and developing novel compounds with improved efficacy and safety profiles. In summary, Duvelisib's role in chemical synthesis lies in its capacity to modulate PI3K signaling pathways, offering new opportunities for drug discovery and therapeutic intervention.

Literature

• Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

  Journal of molecular biology 20170217

• PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

  Chemistry & biology 20131121